We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Gyre Therapeutics Inc (GYRE) USD0.001

Sell:$14.84 Buy:$15.00 Change: $0.77 (5.41%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$14.84
Buy:$15.00
Change: $0.77 (5.41%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$14.84
Buy:$15.00
Change: $0.77 (5.41%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Gyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in the research, development, manufacturing and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). The Company is also advancing a diverse pipeline in China through a controlling interest in Beijing Continent, including pirfenidone, F573, F528, and F230. Pirfenidone is used for idiopathic pulmonary fibrosis and is undergoing Phase III trials in dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, along with a Phase I trial in diabetic kidney disease. F573 is being investigated for acute-on-chronic liver failure, while F528 and F230 are being evaluated for chronic obstructive pulmonary disease and pulmonary arterial hypertension, respectively.

Contact details

Address:
12770 High Bluff Drive, Suite 150
SAN DIEGO
92130
United States
Telephone:
+1 (619) 9493681
Website:
https://www.gyretx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GYRE
ISIN:
US4037831033
Market cap:
$1.22 billion
Shares in issue:
85.51 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Songjiang Ma
    President, Director
  • Han Ying
    Chief Executive Officer, Director
  • Ruoyu Chen
    Interim Chief Financial Officer
  • Weiguo Ye
    Chief Operating Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.